Clinical TrialsSearch results
Number of results: 255
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Phase III Clinical Study on Taste Disorder by Z-103
-Double Blind Comparison Study on Patients with Zinc-Deficient and Idiopathic Taste Disorders -
- Zinc-Deficient and Idiopathic Taste Disorders
- ZERIA Pharmaceutical Co.,Ltd.
- 2006-04-10
Other
- Phase III study of Z-100 in uterine cervix cancer patients
- primary uterine cervix cancer
- ZERIA Pharmaceutical Co.,Ltd.
- 2005-09-13
Other
- A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma:
the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial
- Gastric Cancer
- Young Leaders' Program (YLP), Nagoya University School of Medicine
- 2005-09-01
Other
- Effects of a traditional Japanse herbal medicine yokukansan (YKS) for BPSD in DLB
- Dementia with Lewy bodies (DLB), Parkinson disease with dementia (PDD)
- yokukansan-DLB research group
- 2008-11-20
Other
- Meaninglessness in terminally ill cancer patients: Doctor Education Intervention Trial
- Spiritual pain
- Yasunori Matoba, M.D., PhD.
- 2009-01-02
Other
- Phase II study of R-CHOP and R-high-dose MTX therapy for IVLBCL
- Intravascular large B-cell lymphoma
- Yamaguchi Motoko
- 2019-03-29
Completed
- PEARL5 study
- CD5-positive diffuse large B-cell lymphoma
- Yamaguchi Motoko
- 2019-03-29
Other
- Multi-institute randomized study of natural type interferon alpha for patients with renal cell carcinoma after radical nephrectomy
- Renal cell carcinoma
- TRAIn-Alpha study group
- 2005-09-30
Other
- Study of Docetaxle and trastuzumab as preoperative chemotherapy for advanced-stage breast cancer with HER2 over expression
- Breast Cancer
- Toukai Breast Cancer Clinical Reserch Group
- 2005-09-12
Completed
- Repurposing bromocriptine for Abeta metabolism in Alzheimer's disease
- Alzheimer's disease patients with PSEN1 mutations
- Tomimoto Hidekazu
- 2020-04-30